CytRx’s Aldoxorubicin (INNO-206) Clinical Data To Be Featured At The ESMO 2012 Congress

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, announced that favorable results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate aldoxorubicin (formerly known as INNO-206) primarily in patients with advanced soft tissue sarcoma will be featured in a poster presentation at the ESMO (European Society of Medical Oncology) 2012 Congress being held September 28 - October 2 in Vienna, Austria.

The abstract “INNO-206 is an active drug for relapsed advanced soft tissue sarcoma” will be presented by the clinical trial’s principal investigator and renowned sarcoma expert Sant P. Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center in Santa Monica, Calif. The abstract will be published in the ESMO 2012 Congress Abstract Book, which is a supplement to the peer-reviewed ESMO journal Annals of Oncology.

On June 3, 2012, CytRx reported data from the Phase 1b/2 trial showing clinical benefit (defined as partial response and stable disease of more than four months following up to eight cycles of treatment) with aldoxorubicin at the maximum tolerated dose in 10 of 13 (76.9%) evaluable patients with relapsed or refractory soft tissue sarcoma. CytRx holds exclusive worldwide rights to aldoxorubicin, as well as to the protein-binding platform technology that serves as the linker with doxorubicin. The Company plans to meet with the FDA in the second half of 2012 to discuss a potential Phase 3 pivotal trial for aldoxorubicin as therapy for patients with soft tissue sarcomas who have relapsed after or were refractory to chemotherapy.

“We are delighted with the opportunity to gain greater visibility for these impressive clinical results with aldoxorubicin from the international oncology community,” said Steven A. Kriegsman, CytRx President and CEO. “The acceptance of this abstract is noteworthy as the ESMO conference serves as a platform for the presentation of the latest oncology research and the Annals of Oncology is known for publishing new oncology findings and for its high scientific quality. We thank Dr. Chawla for his continued support and for taking his valuable time to present the aldoxorubicin data.”

About the European Society for Medical Oncology

The European Society for Medical Oncology (ESMO) is the leading European professional organization committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care. Since its founding in 1975 as a non-profit organization, the ESMO’s mission has been to advance cancer care and cure.

1 2 3 Next › Last »